Illumina Ventures and M Ventures made follow-on investments in synthetic DNA platform developer DNA Script as part of its $38.5m series B round.
France-based synthetic DNA producer DNA Script secured $38.5m on Friday in a series B round featuring Illumina Ventures and M Ventures, respective subsidiaries of genetic technology producer Illumina and pharmaceutical firm Merck Group.
Public investment bank BPIfrance also supplied series B funding, as did investment firm Idinvest Partners and life sciences-focused venture capital firms LSP and Kurma Partners.
Founded in 2014, DNA Script has built a system that exploits enzymatic and nucleotide biochemical processes to produce synthetic DNA at the…
